BACKGROUND: We aimed at estimating pneumococcal serotype-specific disease potential in pediatric community-acquired alveolar pneumonia (CAAP), by comparing nasopharyngeal pneumococcal carriage during disease to carriage in healthy children. METHODS: Pneumococcal nasopharyngeal cultures were obtained from children < 5 years old admitted to the emergency room or hospitalized with radiologically diagnosed CAAP and from healthy controls. Disease potential was estimated by calculating serotype-specific odds ratios (OR) of a given serotype to be carried during disease compared with healthy children (after adjustment for age, ethnicity, previous antibiotic therapy, and season). RESULTS: A total of 603 and 1504 isolates were obtained from CAAP and healthy children, respectively. A significant OR > 1.0 of a specific serotype being carried during disease (suggesting a higher disease potential) was observed with serotypes (by decreasing rank) 1, 5, 22F, 7F, 14, 9V, and 19A. A significant OR < 1.0 of being carried during disease (suggesting a lower disease potential) was observed with serotypes 6A, 6B, 23A, and 35B. Carriage of PCV7 serotypes (grouped) during CAAP was highest in age group 6 to 17 months. PCV10 and PCV13 provided significantly higher coverage for both 6 to 17 and 18 to 35 month age groups. CONCLUSIONS: It is suggested that serotypes 1, 5, 7F, 9V, 14, 19A, and 22F have a higher disease potential for childhood pneumonia than do serotypes 6A, 6B, 23A, and 35B.
BACKGROUND: We aimed at estimating pneumococcal serotype-specific disease potential in pediatric community-acquired alveolar pneumonia (CAAP), by comparing nasopharyngeal pneumococcal carriage during disease to carriage in healthy children. METHODS:Pneumococcal nasopharyngeal cultures were obtained from children < 5 years old admitted to the emergency room or hospitalized with radiologically diagnosed CAAP and from healthy controls. Disease potential was estimated by calculating serotype-specific odds ratios (OR) of a given serotype to be carried during disease compared with healthy children (after adjustment for age, ethnicity, previous antibiotic therapy, and season). RESULTS: A total of 603 and 1504 isolates were obtained from CAAP and healthy children, respectively. A significant OR > 1.0 of a specific serotype being carried during disease (suggesting a higher disease potential) was observed with serotypes (by decreasing rank) 1, 5, 22F, 7F, 14, 9V, and 19A. A significant OR < 1.0 of being carried during disease (suggesting a lower disease potential) was observed with serotypes 6A, 6B, 23A, and 35B. Carriage of PCV7 serotypes (grouped) during CAAP was highest in age group 6 to 17 months. PCV10 and PCV13 provided significantly higher coverage for both 6 to 17 and 18 to 35 month age groups. CONCLUSIONS: It is suggested that serotypes 1, 5, 7F, 9V, 14, 19A, and 22F have a higher disease potential for childhood pneumonia than do serotypes 6A, 6B, 23A, and 35B.
Authors: W C Albrich; S A Madhi; P V Adrian; N van Niekerk; T Mareletsi; C Cutland; M Wong; M Khoosal; A Karstaedt; P Zhao; A Deatly; M Sidhu; K U Jansen; K P Klugman Journal: Clin Infect Dis Date: 2011-12-08 Impact factor: 9.079
Authors: K A Feemster; Y Li; A R Localio; J Shults; P Edelstein; E Lautenbach; T Smith; J P Metlay Journal: Epidemiol Infect Date: 2012-10-31 Impact factor: 2.451
Authors: C Lemaître; A Ferroni; C Doit; H Vu-Thien; C Glorion; J Raymond; P Mary; P Wicart; E Bingen; B Ilharreborde; M Lorrot Journal: Eur J Clin Microbiol Infect Dis Date: 2012-05-09 Impact factor: 3.267
Authors: Elena Mitsi; Beatriz Carniel; Jesús Reiné; Jamie Rylance; Seher Zaidi; Alessandra Soares-Schanoski; Victoria Connor; Andrea M Collins; Andreas Schlitzer; Elissavet Nikolaou; Carla Solórzano; Sherin Pojar; Helen Hill; Angela D Hyder-Wright; Kondwani C Jambo; Marco R Oggioni; Megan De Ste Croix; Stephen B Gordon; Simon P Jochems; Daniela M Ferreira Journal: Am J Respir Crit Care Med Date: 2020-02-01 Impact factor: 21.405
Authors: Olumuyiwa O Odusanya; Yetunde A Kuyinu; Omolara A Kehinde; Fakrudeen Shafi; Nancy François; Juan Pablo Yarzabal; Kurt Dobbelaere; Jens U Rüggeberg; Dorota Borys; Lode Schuerman Journal: Hum Vaccin Immunother Date: 2013-12-04 Impact factor: 3.452
Authors: Werner C Albrich; Shabir A Madhi; Peter V Adrian; Nadia van Niekerk; Jean-Noel Telles; N Ebrahim; Melina Messaoudi; Glaucia Paranhos-Baccalà; Sven Giersdorf; Guy Vernet; Beat Mueller; Keith P Klugman Journal: BMJ Open Date: 2014-08-11 Impact factor: 2.692